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Severe defect in clearing postprandial chylomicron remnants in dialysis
patients. Lipid abnormalities have been suggested as a major cause of
the accelerated atherosclerosis and the high incidence of coronary heart
disease in chronic renal failure patients. In the present work the
postprandial lipoprotein metabolism was studied in chronic dialysis
patients with or without fasting hypertriglyceridemia using the vitamin
A loading test. This method investigates specifically postprandial lipo-
protein metabolism. The determination of vitamin A ester level retinyl
palmitate (RP) differentiates the circulating plasma chylomicron and
chylomicron remnant fractions from the endogenous VLDL and IDL.
Subjects with normal renal function with or without fasting hypertn-
glyceridemia served as control groups. Dialysis patients have signifi-
cantly higher level of chylomicron remnants for a more prolonged
period of time than controls, irrespective of their fasting triglyceride
levels. The area below retinyl palmitate chylomicron remnants curve
was 26308 12422 sg/liter' hr in the normolipidemic dialysis patients,
significantly higher than (6393 2098 tgIliter' hr; P < 0.0001) in the
normolipidemic controls. The retinyl palmitate chylomicron remnants
curve of the hypertriglyceridemic dialysis patients was 21021 4560
gIliter' hr, which was higher than 12969 2215 pg/liter' hr (P <
0.0001) in the hypertriglyceridemic controls. Moreover, the hypertri-
glyceridemic dialysis patients had an additional defect in the lipolysis
metabolic step, that is, accumulation of chylomicrons in circulation.
These findings show a severe defect in postprandial lipoprotein metab-
olism in chronic renal failure patients. The prolonged exposure of the
vascular wall to high chylomicron remnant concentrations might be an
important pathogenetic factor in the accelerated atherosclerosis seen in
chronic dialysis patients.
Chronic dialysis patients have a high incidence of coronary
heart disease and accelerated atherosclerosis [1—4]. The renal
and internal iliac arteries of uremic patients have been found to
have accelerated atherosclerotic and vascular aging changes as
compared with vessels from control populations [5, 61. Cardio-
vascular death is a leading cause of mortality in dialysis patients
[71. Although many factors undoubtedly contribute to acceler-
ated atherosclerosis, lipid abnormalities have been suggested as
a major cause, and hyperlipidemia is associated with increased
cardiovascular mortality [8—10]. The association between the
two is now well accepted, and many recent studies have
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focused on the nature and significance of lipid abnormalities in
patients with renal disease [11—14].
The lipid abnormalities in chronic renal failure are hypertri-
glyceridemic (hyper TG), high VLDL levels, triglyceride en-
richment of LDL and HDL, and reduced HDL cholesterol [4,
15—17]. However, the degree of hypertriglyceridemic reported
in chronic renal failure (CRF) is only moderate, and according
to epidemiologic surveys of normal populations such hyper TG
would lead to only a marginal increase in the risk of coronary
heart disease [18]. It is therefore possible that other lipoproteins
with greater atherogenic potential than VLDL are found in
these patients and are responsible for the accelerated athero-
sclerosis. Chylomicron remnants, intestinal-derived lipopro-
teins and VLDL remnants (IDL) are known to be very athero-
genic lipid particles causing premature peripheral vascular
disease and coronary heart disease in patients with type III
hyperlipidemia [19, 20]. Recent studies have suggested that the
presence of fasting chylomicron remnants (cmr) in patients with
CRF may contribute to the increased incidence of coronary
heart disease [21—25]. However, these studies were based on
indirect evidence only, because of difficulties in differentiating
between intestinal-derived lipoproteins and endogenous VLDL
and in investigating their metabolism [26].
It is also not known whether such a metabolic defect occurs
only in hyper TO renal failure dialysis patients or even in
normotriglyceridemic patients.
A new method for investigating the metabolism of postpran-
dial lipoproteins in humans has been introduced [271. It consists
of the determination of Vit A ester levels in plasma following
the feeding of a vitamin A (Vit A) fat meal. The Vit A is
absorbed, becomes esterified in the intestinal absorbtive cells,
and is secreted with chylomicrons. The retinyl ester, mainly
retinyl palmitate (RP), circulates with the chylomicron and cmr
and is finally taken up with the remnant particles by liver cells.
Therefore, the appearance and disappearance of RP in plasma
lipoproteins and their remnants reflect the postprandial circu-
lating lipoprotein metabolic steps [28], In previous studies using
the Vit A fat method we have shown that this is a sensitive and
highly specific method, and have directly demonstrated the
accumulation of chylomicron remnants in type III hyperlipid-
emia [29—32].
The aim of the present work was to study the postprandial
lipoprotein metabolism using the Vit A fat loading test in
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end-stage renal failure dialysis patients with or without fasting
hyperlipidemia.
Methods
Patients
Twenty-one chronic renal failure adult patients on regular
dialysis and 24 subjects with normal renal function participated
in the study.
Group I. Fifteen subjects (7 females and 8 males) with no
renal disease and normal renal function, and normal fasting
plasma lipids.
Group 2. Nine hypertriglyceridemic patients (3 females and 6
males) with normal renal function.
Group 3. Thirteen patients (5 females and 8 males) with
end-stage renal failure. Seven were on maintenance hemodial-
ysis (HD) at least three months, for three times four hours per
week, and six on continuous ambulatory peritoneal dialysis
(CAPD), who had been at least three months free from perito-
nitis. All these patients had normal fasting triglyceride levels.
Group 4. Eight patients (3 females and 5 males) with CRF
with high fasting TG levels (4 on hemodialysis and 4 on CAPD).
None of the patients had liver disease, hypothyroidism, diabe-
tes mellitus, or nephrotic syndrome. The criteria for normal
lipids were fasting total cholesterol <240 mgldl and plasma
triglycerides <180 mg/dl. The criteria for hypertriglyceridemia
was plasma TG >280 mg/dl.
Sixteen of the dialysis patients had documented myocardial
infarction in their medical history.
Vitamin A fat loading test
The test Was performed as recently described [31]. After an
overnight 12 hour fast, subjects were given a fatty meal plus
60000 U of aqueous vitamin A/rn2 body surface. The fatty meal
contained 50 g of fat/m2 body surface, consisting of 65%
calories as fat, 20% as carbohydrate and 15% as protein. It
contained 600 mg cholesterol/l000 calories, and the P/S ratio
was 0.3. This was given as a milkshake, scrambled eggs, bread
and cheese, and was consumed in 10 minutes.
The vitamin A was added to the milkshake. After the meal,
the subjects fasted for 10 hours, but drinking water was allowed
as desired. Blood samples were drawn before the meal and
every hour after the meal. All subjects tolerated the meal well,
without diarrhea or other symptoms of intestinal dysfunction.
Laboratory determinations
The blood samples were drawn in sodium EDTA containing
test tubes and were immediately centrifuged at 1500 g for 15
minutes. One ml of plasma was stored wrapped in foil at —20°C
for total plasma retinyl ester assay. Another sample of 0.5 ml
was stored at 4°C for triglyceride determinations. Another 2.5
ml of plasma was transferred into a 1/2 x 2 inch cellulose nitrate
tube and overlayered with 2,5ml sodium chloride solution (d =
1.006 g/ml). Tubes were subjected to preparative ultracentri-
fugation for 1.6 x 106 g mm with a rotor (SW-55; Beckman
Instruments, Inc., Fullerton, California, USA) to float chylo-
micron particles of Sf >1,000 [311.
The chylomicron containing supernatant (chylomicron frac-
tion), was removed and brought to a total volume of 5 ml with
saline. The infranatant (chylomicron remnant fraction) was
brought to a volume of 5 ml with saline. Alliquotes of superna-
tant and infranatant (0.5 ml) were wrapped in foil and assayed
for retinyl ester. Additional aliquots were assayed for triglyc-
eride concentration. This procedure appears to separate a
predominantly chylomicron population from a predominantly
chylomicron remnant population [31, 321.
Retiny! ester determination
Retinyl palmitate was determined in total plasma (TP),
plasma chylomicron fraction (CM) and plasma chylomicron
remnants fraction (CMR). The assays were carried out in
subdued light with HPLC grade solvents. Retinyl acetate was
added to the samples as an internal standard. The samples were
then mixed with ethanol 4 ml, hexane 5 ml and water 4 ml with
vortexing between each addition. Two phases were formed and
4 ml of the upper (hexane) phase was removed and evaporated
under nitrogen [33]. The residue was dissolved in a small
volume of benzene, and an aliquote was injected into an HPLC
5 sm ODS-l8 radial compression column. One hundred percent
methanol was used as a mobile phase at a flow rate of 2 ml/min.
The effluent was monitored at 340 nm and the peak of retinyl
palmitate (RP) was identified by comparison to the retention
time of purified standard (Sigma Chemical Co., St. Louis,
Missouri, USA). In agreement with previous reports [301 it was
found that 75 to 80% of total plasma retinyl esters were
accounted for by retinyl palmitate. In addition the distribution
of retinyl esters remained constant throughout the study.
Lipid and lipoprotein determinations
Cholesterol and triglycerides were measured enzymatically
using the reagents cholesterol 236991 and triglycerides 126012
(Boehringer Mannheim, Inc., Indianopolis, Indiana, USA).
HDL cholesterol was determined after precipitation of plasma
with dextran sulfate-magnesium.
Statistical analysis
Data are presented as mean SD, using the unpaired Stu-
dent's t-test with Bonferroni's correction to compare control
and chronic renal failure groups within the categories of nor-
molipidemic or hypertriglyceridemic groups.
The amounts of retinyl palmitate in total plasma, plasma
chylomicron fraction and plasma chylomicron remnant fraction
were quantified by the ratio method [34] using retinyl acetate as
a reference [31].
Two way analysis of variance with repeated measurements
was used to assess significant differences between groups. (The
Statview MAC II program was used for statistical analysis).
Results
The fasting plasma lipids and lipoprotein levels in the studied
groups are given in Table 1. Both normal and high fasting
triglyceridemic dialysis groups had significantly lower mean
HDL-cholesterol than the normal controls. Total plasma,
plasma chylomicron fraction and plasma chylomicron remnant
fraction, retinyl palmitate concentration after vitamin A fat
loading test are given in Figure 1, and Table 2.
Control subjects vith normal renal function
Normolipidemic subjects. Total plasma retinyl palmitate was
detectable one hour after the Vit A fat meal, increased rapidly
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Table 1. Fasting plasma lipids and lipoproteins, age, sex and body surface area (BSA) in the studied groups
between one and four hours, remained high until six hours,
declined rapidly between six and 10 hours to reach about 25%of
peak levels, the plasma chylomicron and plasma chylomicron
remnant fractions appeared to behave differently. The plasma
chylomicron fraction RP levels closely paralleled those of total
plasma RP. The plasma chylomicron remnant fraction RP levels
were lower than chylomicron RP levels, increasing to peak
levels between three and six hours, remaining unchanged until
eight hours and then slowly decreased. At nine to ten hours
their concentration exceeded the chylomicron RP concentra-
tions.
Hyperlipide,nic subjects. Plasma, chylomicron and chylomi-
cron remnants RP concentrations were abnormal compared
with the normolipidemic control persons. The RP of the two
lipoprotein fractions were several-fold higher then in the normal
group. The most impressive differences were found in the total
plasma and plasma chylomicron fraction RP peak levels and
areas below RP curves, demonstrating a high accumulation and
a very slow disappearence of chylomicron RP.
Chronic renal failure dialysis patients
Normolipidemic patients. Both hemodialysis and continuous
ambulatory peritoneal dialysis patients had similar responses to
the Vit A fat loading test and were taken as a group.
The normolipidemic dialysis patients had a twofold higher
total plasma RP peak level compared with the respective
control group, 8834 3042 pg/liter and 4206 1923 pg/liter, P
< 0.0003. The RP peak appeared at six hours and declined
slowly to 60% of its peak at 10 hours.
The very high total plasma RP levels were caused mainly by
the accumulation of RP in the plasma chylomicron remnants
fraction.
The RP in the chylomicron remnants fraction had a peak
mean value of 4942 1984 zg/liter significantly higher then in
the normal kidney function normolipidemic group 1420 630
jig/liter, P < 0.0023.
The plasma chylomicron remnants fraction peak was found at
six hours and remained almost unchanged at 10 hours.
The mean value of the area under the chylomicron remnants
RP curves was 26308 12422 /.Lg/liter/hr, fourfold higher than in
the normal renal function normolipidemic controls 6393 2098
g!liter/hr, P < 0.0003.
Hyperlipidemic dialysis patients
The dialysis patients with high fasting triglycerides had
abnormal chylomicron clearance as found in the hypertriglyc-
endemic patients with normal kidney function. In addition the
dialysis patients had a severe defect in the clearance of the
chylomicron remnants. The peak plasma chylomicron remnant
fraction was twofold higher than the normal kidney function
hyperlipidemic patients.
The chylomicron/chylomicron remnant ratio was 3 in the
hypertriglyceride normal kidney function group and 1.2 in the
respective dialysis group. In normolipidemic normal kidney
function patients this ratio is 2.1.
Total plasma triglyceride after Vitamin A fat loading test
The results of each group of subjects are given in Figure 2 and
Table 2.
In the two hypertriglyceridemic groups there was a severe
defect in the triglyceride clearance after the fatty meal. In the
hypertriglyceridemic normal kidney function subjects, peak
levels and areas below triglyceride curves were 896 151 mg/dl
and 8442 1092 mg/dl hr, respectively. In the hypertriglycer-
idemic patients on dialysis the peak levels and area under the
curve were 767 174 rng/dl and 4708 764 mgldl 'hr.
In the normolipidemic dialysis patients the triglyceride peak
levels and the area under triglyceride curves were only slightly
increased, 355 88 mg/dl and 2116 546 mgldl ' hr compared
with 246 76 mg/dl and 1516 374 mg/dl hr, respectively, in
the normolipidemic control persons.
Discussion
The degree of hypertriglycenidemia in patients with chronic
renal failure on dialysis does not correlate well with the
increased risk of coronary heart disease [181. Some studies have
suggested that accumulation of other lipids or lipoproteins,
including circulating chylomicron remnants may play a role in
the increased development of atherosclerosis in these patients
[21—251.
Chylomicrons are synthesized in the intestine following fat
ingestion. They contain APO B-48, APO A-I, APO A-IV. After
secretion they acquire C apolipoproteins and APO E, trans-
ferred from HDL. After hydrolysis by lipoprotein lipase, these
particles are referred to as chylomicron remnants. The particles
are then taken up by the hepatic APO E receptors (exogenous
pathway). The VLDL with its main protein APO B-l00 assem-
bled in the endoplasmatic reticulum of hepatocytes once in the
circulation are hydrolyzed to remnant particles IDL and to
LDL particles and cleared by LDL receptors (endogenous
pathway).
Sex
F M
BSA
m TC
Plasma lipids and lipoproteins mg/d!
Group Age HDL-C
7 1.75 210 l0l 144 soaNormolipidemic 58 8
controls (N = 15) (5) (0.12) (22) (21) (12) (5.2)
HyperTG 59 6 3 1.77 259 528a 135 33
controls (N = 9) (Il) (0.14) (34) (lOS) (14) (3)
Normolipidemic 63 8 5 1.75 200 157 133 36
CRF (N = 13) (10) (0.11) (33) (31) (30) (6)
HyperTG 58 5 3 1.81 223 346 141 35
CRF (N = 8) (9) (0.12) (26) (41) (24) (4.2)
TG LDL-C
Numbers are mean (SD).
a P < 0.05 vs. the respective chronic renal failure group (unpaired I-test)
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Fig. 1. Retinyl pal,nitate (RP) concentration curves in chronic renal failure (CRF) patients and control groups. Total plasma (•----•),
chylomicron fraction (O----O) and chylomicron remnant fraction (Y----V). RP concentrations were determined for CRF patients with normal
fasting lipids (N = 13), and with hypertriglyceridemia (N = 8) and in individuals with normal renal function with normal fasting lipids (N = 15)
and with hypertriglyceridemia (N = 9). For each group the levels at each time point were averaged. Two way analysis of variance with repeated
measurements between groups: for total plasma RP, F value = 17.3 15, P < 0.0001, for RP chylomicron fraction, F value = 13.593, P < 0.0001,
for RP chylomicron remnants fraction, F value = 23.38, P < 0.0001.
The Vit A fat loading test differentiates between the chylo-
microns and chylomicron remnants from VLDL and IDL
despite their similar physical and chemical properties. It also
follows the metabolic steps of these lipoproteins, and thus is
able to detect possible defects in both lipolysis or chylomicron
remnant liver uptake [31, 32].
The present findings demonstrate a severe defect in postpran-
dial lipoprotein metabolism in chronic renal failure patients.
The main metabolic defect is not in the lipolysis step. This is
evidenced by only a slight accumulation of plasma chylomicron
fractions. Furthermore, the lipolysis, as shown by the postpran-
dial triglyceride curves in normolipidemic dialysis patients,
were similar to those in the normolipidemic nonrenal failure
group.
The main defect that causes the accumulation of the post-
prandial lipoproteins in these patients was the chylomicron
remnant uptake by the liver. This results in a threefold accu-
mulation of these lipid particles in the circulation. Thus the
arterial wall of these patients on dialysis might be exposed to
high postaprandial circulating chylomicron remnants during
long periods of time. This metabolic defect occurs in both
normolipidemic and hyperlipidemic dialysis patients. More-
over, the chronic renal failure patients with fasting hypertri-
glyceridemia have the same defect in the hydrolysis as persons
with hypertriglyceridemia and normal renal function. This is
evidenced by the accumulation of plasma chylomicron fraction
and the postprandial total plasma triglycerides curves. A posi-
tive correlation exists between the postprandial plasma chylo-
micron fraction curves and the plasma fasting triglycerides [31].
This reflects competition between the absorbed exogenous fat
and the triglyceride's endogenous origin [35]. A similar defect in
postprandial lipoprotein metabolism as in the normolipidemic
dialysis patients occurs in type III hyperlipidemia. In this
condition the removal of chylomicron remnants is not normal,
Hypertriglyceridemic10000
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4000
2000
0
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0
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Table 2. Plasma triglyceride (TO), retinyl palmitate (RP), peak levels
and area under the curves in the total plasma (TP), chylomicron
fraction (CM), chylomicron remnant fraction (CMR) in
normolipidemic and hypertriglyceridemic (Hyper TO) patients with
chronic renal failure (CRF) and with normal kidney function
Groups
Normol
Control
(N = 15)
ipidemic
CRF
(N = 13)
Hype
Control
(N = 9)
r TG
CRF(N = 8)
Peak levels
Plasma TG 246 355 896 767k
mg/dl (76) (88) (151) (174)
RP pg/liter
TP 4206
(1923)
8834
(3042)
9023
(1232)
8610
(1612)
CM 3118
(1421)
4505
(1794)
6907
(1297)
568l
(1587)
CMR 1420
(630)
4942k
(1984)
2373
(452)
4987k
(1414)
Area under the curves
PlasmaTg 1516 2ll6 8442 4708k
mg/d1 hr (374) (546) (1509) (764)
RP pg/liter hr
TP 21202
(6947)
49566
(22401)
61159
(11243)
48570
(8022)
CM 14815
(5755)
23257
(11791)
47613
(11212)
2769l
(7378)
CMR 6393
(2098)
26308k
(12422)
12696
(2215)
2l02l
(4560)
Data are mean (SD).
a Significantly different from the respective control group (unpaired
Student's i-test with Bonferroni correction)
Reprint requests to Dr. Adrian laina, Department of Nep/zrology, Tel
Aviv Medical Center, lchilov Hospital 6 Weizman Str., Tel Aviv 64239,
Israel,
Fig. 2. Triglyceride concentration (TG) curves in chronic renal failure
(CRF) patients and control groups. Total plasma triglyceride concen-
trations were determined for CRF patients with normal fasting lipids(• •) (N = 13), and with hypertriglyceridemia (V----V) (N = 8)and
for individuals with normal renal function with normal fasting lipids
(O----O) (N = 15) and with hypertriglyceridemia (L1----LJ) (N = 9). For
each group the levels at each time point were averaged. Two way
analysis of variance with repeated measurements between groups: F
value = 147.8, P < 0.0001.
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